Literature DB >> 1279442

Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression.

N Nabavi1, G J Freeman, A Gault, D Godfrey, L M Nadler, L H Glimcher.   

Abstract

Class II major histocompatibility complex (MHC) molecules function as antigen-presenting elements as well as signal transducers on B lymphocytes. We previously reported that a B lymphoma cell transfectant, 5C2, expressing genetically engineered I-Ak molecules with truncated cytoplasmic domains was severely impaired in both antigen presentation and in anti-Ia-induced intracytoplasmic signalling. These two functions could be restored by preculturing 5C2 cells with cyclic AMP analogues. Here we demonstrate that impaired signal transduction by truncated class II molecules results in a deficiency in induction of the newly defined B-cell accessory molecule B7 (ref. 8), which can be reversed by restoration of B7 expression. These data imply that contact of the T-cell antigen receptor with MHC/antigen ligand results in signal transmission through the class II cytoplasmic domain. This signal, which can be mimicked by dibutyryl cAMP, induces expression of B7, resulting in effective antigen presentation. The fact that crosslinking of surface class II MHC also induces B7 expression on normal resting human B cells supports this contention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279442     DOI: 10.1038/360266a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  69 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Recessive expression of the H2A-controlled immune response phenotype depends critically on antigen dose.

Authors:  G Barcenas-Morales; M Merkenschlager; F Wahid; R Döffinger; J Ivanyi
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

Review 3.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

Review 4.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

5.  Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.

Authors:  R Belani; G J Weiner
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

6.  Two distinct pathways of human macrophage differentiation are mediated by interferon-gamma and interleukin-10.

Authors:  T Orlikowsky; T Olikowsky; Z Q Wang; A Dudhane; H Horowitz; B Conti; M K Hoffmann
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

7.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

Authors:  B D Hock; G C Starling; P B Daniel; D N Hart
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

8.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

9.  Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation.

Authors:  N Amirayan; E Furrie; F Deleuil; A Mellor; L Leserman; P Machy
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Antibodies to major histocompatibility complex class II inhibit proliferation, but increase production of soluble CD23 in lymphoblastoid B-cell lines.

Authors:  A H Hajeer; N Snowden; P Wilson; S Drover; W E Ollier
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.